Mark Boyd

Professor Mark Boyd

Chair of Medicine

Adelaide Medical School

Faculty of Health and Medical Sciences


Professor Boyd is an internationally recognised infectious disease expert. He has led project teams in HIV research in Thailand, as well as at the Kirby Institute for infection and immunity at the University of New South Wales. He has published results from randomised trials that changed international guidelines for the treatment of adults living with HIV worldwide.

Since moving to the University of Adelaide based at the Lyell McEwin Hospital in Adelaide's north, Boyd has shifted his attention to the health needs of people living in the substantially disadvantaged communities that the hospital serves. Transformative improvements in health and wellbeing in these communities will not come from better access to new pharmaceutical magic bullets, but from interventions that decrease the extreme social stress under which many people live - financial instability, housing insecurity, food scarcity, etc. . The challenge is to reconfigure the health system to not only provide the standard pharmaceutical and technical solutions, but also work to help solve the social stressors. This guides our research and our passion for meaningful change in healthcare delivery.

Research

My research interests include:

  • combining an understanding of patients' social context and stressors and intervening as an essential component of healthcare. The goal is the define a healthcare bundle that combines this critical aspect of healthcare with the standard technological and pharmaceutical interventions. This domain is little researched and requires it. There are numerous aspects of this that could provide innovative, fruitful projects from Honours all the way to a PhD. I am very happy to be contacted to discuss and work with students to find something agreeable to all.
  • the pathogenesis and clinical management of HIV infection. Before moving to UofA I spent nearly 20 years doing HIV clinical research. I have seen this viral infection move from a death sentence to a readily manageable chronic disease. I maintain a presence and reputation in the HIV world and continue to be engaged in national and international research projects in which there is potential for HDR projects based in Adelaide. 
  • as the Chair of Medicine at the Lyell McEwin Hospital with expertise in clinical trial design  I am involved in developing research of all kinds across the full spectrum of medical practice, e.g. hepatology, gastroenterolgy, respiratory, cardiology, etc. I would be more than happy to answer queries about research projects being conducted at the Lyell McEwin Hospital (or Modbury Hospital) to see if we can find something suitable.
    Expand
  • Appointments

    Date Position Institution name
    2015 - 2016 Visiting Medical Officer Murrumbidgee Health District
    2015 - 2016 Visiting Medical Officer Albury Wodonga Health District
    2013 - 2016 Associate Professor University of New South Wales
    2007 - 2012 Clinical Project Leader St Vincent's Hospital
    2004 - 2007 Senior Consultant in Infectious Diseases and Microbiology Flinders Medical Centre
    2000 - 2004 Clinical Project Leader HIV Netherlands Australia Thailand Research Collaboration
  • Awards and Achievements

    Date Type Title Institution Name Country Amount
    2014 Award The Frank Fenner Award for Advanced Research in Infectious Diseases Australasian Society for Infectious Diseases (ASID) Inc.
    2014 Award Outstanding Reviewer for 2013
    1986 Award The Alfred Houston Senior Prize in Philosophy University of Tasmania
  • Education

    Date Institution name Country Title
    2006 Flinders University Australia (MHID) - Master of Health and International Development
    2001 - 2006 University of New South Wales Australia MD - Doctor of Medicine
    1997 University of Alabama (USA) and Universidad Peruana Cayetano-Heredia (Perú) Peru and United States DCTM&H - Dip. In Clinical. Trop. Med. and Hygiene
    1987 - 1992 Flinders University Australia BM, BS Medicine, Surgery
    1983 - 1986 University of Tasmania Australia BA Philosophy - English Literature
  • Certifications

    Date Title Institution name Country
    2013 Graduate Certificate in University Learning and Te University of New South Wales Australia
    2011 Certificate for Ethics Training for Human Research Monash University Australia
    1995 Fellowship Royal Australasian College of Physicians Australia
  • Research Interests

    Expand
  • Journals

    Year Citation
    2019 Bell, S., Mena, G., Dean, J., Watts, P., Howard, C., Boyd, M., . . . Gartner, C. (2019). Addressing smoking among people living with HIV: a cross-sectional survey of Australian HIV health practitioners’ practices and attitudes. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 31(4), 436-442.
    DOI
    2019 Boyd, M., Boffito, M., Castagna, A., & Estrada, V. (2019). Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps. HIV Medicine, 20, 3-11.
    DOI Scopus1 WoS1
    2019 McManus, H., Callander, D., Donovan, B., Russell, D., O'Connor, C., Davies, S., . . . Guy, R. (2019). Early initiation of antiretroviral therapy for people newly diagnosed with HIV infection in Australia: trends and predictors, 2004–2015. Medical Journal of Australia, 210(6), 269-275.
    DOI Scopus2 WoS1
    2019 Melaku, Y. A., Gill, T. K., Appleton, S. L., Hill, C., Boyd, M. A., & Adams, R. J. (2019). Sociodemographic, lifestyle and metabolic predictors of all-cause mortality in a cohort of community-dwelling population: an 18-year follow-up of the North West Adelaide Health Study.. BMJ open, 9(8), e030079.
    DOI
    2018 Wright, E., Grulich, A., Roy, K., Boyd, M., Cornelisse, V., Russell, D., . . . Zablotska, I. (2018). Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018.. Journal of virus eradication, 4(2), 143-159.
    Europe PMC2
    2018 Giles, M. L., Gartner, C., & Boyd, M. A. (2018). Smoking and HIV: What are the risks and what harm reduction strategies do we have at our disposal?. AIDS Research and Therapy, 15(1), 5 pages.
    DOI
    2018 Stockdale, A., Saunders, M., Boyd, M., Bonnett, L., Johnston, V., Wandeler, G., . . . Geretti, A. (2018). Effectiveness of protease inhibitor/nucleos(t)ide reverse transcriptase inhibitor-based second-line antiretroviral therapy for the treatment of HIV-1 infection in sub-Saharan Africa: systematic review and meta-analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 66(12), 1846-1857.
    DOI Scopus9 WoS8 Europe PMC4
    2018 Boyd, M., & Cooper, D. (2018). Combination ART: are two drugs as good as three?. The Lancet, 391(10123), 817-819.
    DOI Scopus2 WoS2 Europe PMC1
    2018 Mwasakifwa, G., Moore, C., Carey, D., Amin, J., Penteado, P., Losso, M., . . . Boyd, M. (2018). Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy. AIDS, 32(3), 357-361.
    DOI WoS1 Europe PMC1
    2018 Haridy, J., Wigg, A., Muller, K., Ramachandran, J., Tilley, E., Waddell, V., . . . Tse, E. (2018). Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience. Journal of Viral Hepatitis, 25(11), 1287-1297.
    DOI Scopus4 WoS3 Europe PMC1
    2018 Yao, A., Moore, C., Lim, P., Molina, J. -M., Madero, J., Kerr, S., . . . Boyd, M. (2018). Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial. Antiviral therapy, 23(1), 21-32.
    DOI Scopus1 WoS1
    2018 Boyd, M., Cooper, D., & Gilks, C. (2018). Towards a universal second-line fixed-dose combination ART. The Lancet HIV, 5(1), e3-e5.
    DOI Scopus3 WoS3 Europe PMC2
    2017 Boyd, M., Mocroft, A., Ryom, L., d'Arminio Monforte, A., Sabin, C., El-Sadr, W., . . . Law, M. (2017). Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: a prospective analysis of the D:A:D observational study. PLoS Medicine, 14(11), e1002424-1-e1002424-14.
    DOI Scopus4 WoS5 Europe PMC3
    2017 Bell, S., Mena, G., Dean, J., Boyd, M., Gilks, C., & Gartner, C. (2017). Vaporised nicotine and tobacco harm reduction for addressing smoking among people living with HIV: A cross-sectional survey of Australian HIV health practitioners’ attitudes. Drug and Alcohol Dependence, 177, 67-70.
    DOI Scopus2 WoS2 Europe PMC1
    2017 Lau, A., Kong, F., Fairley, C., Donovan, B., Chen, M., Bradshaw, C., . . . Hocking, J. (2017). Treatment efficacy of azithromycin 1 g single dose versus doxycycline 100 mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men - a double-blind randomised controlled trial protocol. BMC Infectious Diseases, 17(1), 35-1-35-9.
    DOI Scopus5 WoS7 Europe PMC5
    2017 Aung, N., Hanson, J., Kyi, T., Htet, Z., Cooper, D., Boyd, M., . . . Saw, H. (2017). HIV care in Yangon, Myanmar; successes, challenges and implications for policy. AIDS Research and Therapy, 14(1), 1-7.
    DOI Scopus2 WoS2 Europe PMC1
    2017 Rhee, S., Varghese, V., Holmes, S., Van Zyl, G., Steegen, K., Boyd, M., . . . Shafer, R. (2017). Mutational correlates of virological failure in individuals receiving a WHO-recommended tenofovir-containing first-line regimen: an international collaboration. EBioMedicine, 18, 225-235.
    DOI Scopus11 WoS10 Europe PMC10
    2017 Boyd, M. (2017). Body composition substudy of the SECOND-LINE study – Author's reply. The Lancet HIV, 4(6), e240.
    DOI
    2017 Bell, S., Dean, J., Gilks, C., Boyd, M., Fitzgerald, L., Mutch, A., . . . Gartner, C. (2017). Tobacco harm reduction with vaporised nicotine (THRiVe): The study protocol of an uncontrolled feasibility study of novel nicotine replacement products among people living with HIV who smoke. International Journal of Environmental Research and Public Health, 14(7), 12 pages.
    DOI Scopus3 WoS3 Europe PMC2
    2017 Boyd, M., & Cooper, D. (2017). Long-acting injectable ART: next revolution in HIV?. The Lancet, 390(10101), 1468-1470.
    DOI Scopus4 WoS4 Europe PMC2
    2017 Thit, S., Aung, N., Htet, Z., Boyd, M., Saw, H., Anstey, N., . . . Hanson, J. (2017). The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study. BMC Medicine, 15(1), 145-1-145-11.
    DOI Scopus3 WoS4 Europe PMC4
    2017 Puhr, R., Petoumenos, K., Youds, D., Law, M., Templeton, D., Ellis, D., . . . Bargh, K. (2017). The impact of changes in HIV management guidelines on time to treatment initiation in Australia. HIV Medicine, 18(9), 701-703.
    DOI Scopus2 WoS2 Europe PMC2
    2017 Boyd, M., Amin, J., Mallon, P., Kumarasamy, N., Lombaard, J., Wood, R., . . . Cooper, D. (2017). Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. The Lancet HIV, 4(1), e13-e20.
    DOI Scopus5 WoS4 Europe PMC4
    2017 Petoumenos, K., Choi, J., Hoy, J., Kiertiburanakul, S., Ng, O., Boyd, M., . . . Law, M. (2017). CD4:CD8 ratio comparison between cohorts of HIV-positive Asians and Caucasians upon commencement of antiretroviral therapy. Antiviral Therapy, 22(8), 659-668.
    DOI Scopus3 WoS2 Europe PMC2
    2017 Wright, E., Grulich, A., Roy, K., Boyd, M., Cornelisse, V., Russell, D., . . . Zablotska, I. (2017). Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines.. Journal of virus eradication, 3(3), 168-184.
    Europe PMC9
    2016 Arts, E., & Boyd, M. (2016). Reviewer acknowledgement.. AIDS research and therapy, 13(1).
    DOI
    2016 Zaunders, J., Danta, M., Bailey, M., Mak, G., Marks, K., Seddiki, N., . . . Koelsch, K. (2016). CD4⁺ T follicular helper and IgA⁺ B cell numbers in gut biopsies from HIV-infected subjects on antiretroviral therapy are similar to HIV-uninfected individuals. Frontiers in Immunology, 7(OCT), 438.
    DOI Scopus5 WoS6 Europe PMC6
    2016 Boyd, M., Cooper, D., Crock, E., Crooks, L., Giles, M., Grulich, A., . . . Yarwood, T. (2016). Sexual transmission of HIV and the law: An Australian medical consensus statement. Medical Journal of Australia, 205(9), 409-412.
    DOI Scopus4 WoS4 Europe PMC2
    2016 Klassen, K., Kimlin, M., Fairley, C., Emery, S., Anderson, P., & Ebeling, P. (2016). Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV. Osteoporosis International, 27(5), 1737-1745.
    DOI Scopus6 WoS6 Europe PMC4
    2016 Lam, E., Moore, C., Gotuzzo, E., Nwizu, C., Kamarulzaman, A., Chetchotisakd, P., . . . Boyd, M. (2016). Antiretroviral resistance after first-line antiretroviral therapy failure in diverse HIV-1 subtypes in the SECOND-LINE study. AIDS Research and Human Retroviruses, 32(9), 841-850.
    DOI Scopus7 WoS7 Europe PMC6
    2016 Achhra, A., Mwasakifwa, G., Amin, J., & Boyd, M. (2016). Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis. The Lancet HIV, 3(8), e351-e360.
    DOI Scopus32 WoS25 Europe PMC19
    2016 Alvarez, E., Belloso, W., Boyd, M., Inkaya, A., Hsieh, E., Kambugu, A., . . . Mallon, P. (2016). Which HIV patients should be screened for osteoporosis: An international perspective. Current Opinion in HIV and AIDS, 11(3), 268-276.
    DOI Scopus8 WoS4 Europe PMC6
    2016 Boyd, M., & Cooper, D. (2016). Novel antiretroviral agents and universal access to HIV care. The Lancet HIV, 3(1), e2-e3.
    DOI
    2016 Winston, A., Stöhr, W., Antinori, A., Arenas-Pinto, A., Llibre, J., Amieva, H., . . . Barea, C. (2016). Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. HIV Medicine, 17(6), 471-478.
    DOI Scopus4 WoS3 Europe PMC4
    2016 Lambert-Niclot, S., George, E., Pozniak, A., White, E., Schwimmer, C., Jessen, H., . . . Couffin-Cadiergues, S. (2016). Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. Journal of Antimicrobial Chemotherapy, 71(4), 1056-1062.
    DOI Scopus14 WoS15 Europe PMC11
    2016 Boyd, M., & Cooper, D. (2016). Tenofovir alafenamide: safer, but questions remain. The Lancet HIV, 3(4), e148-e149.
    DOI Scopus1 WoS1
    2015 Amin, J., Boyd, M., Kumarasamy, N., Moore, C., Losso, M., Nwizu, C., . . . Cooper, D. (2015). Erratum: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection (PLoS ONE (2015)10:2 (e0118228) Doi: 10.1371/journal.pone.0118228 )). PLoS ONE, 10(10), e0140623.
    DOI Scopus3
    2015 Boyd, M., & Cooper, D. (2015). The LATTE study: A provocative brew. The Lancet Infectious Diseases, 15(10), 1116-1117.
    DOI WoS1
    2015 Amin, J., Becker, S., Belloso, W., Boffito, M., Cooper, D., Crabtree-Ramirez, B., . . . Dolan, M. (2015). Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. The Lancet Infectious Diseases, 15(7), 793-802.
    DOI Scopus57 WoS54 Europe PMC36
    2015 Amin, J., Boyd, M., Kumarasamy, N., Moore, C., Losso, M., Nwizu, C., . . . Cooper, D. (2015). Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection. PLoS ONE, 10(2), e0118228.
    DOI Scopus16 WoS15 Europe PMC15
    2015 Han, N., Wright, S., O'Connor, C., Hoy, J., Ponnampalavanar, S., Grotowski, M., . . . Pujari, S. (2015). HIV and aging: Insights from the Asia Pacific HIV Observational Database (APHOD). HIV Medicine, 16(3), 152-160.
    DOI Scopus5 Europe PMC4
    2015 McManus, H., Hoy, J., Woolley, I., Boyd, M., Kelly, M., Mulhall, B., . . . Law, M. (2015). Erratum: Recent trends in early stage response to combination antiretroviral therapy in Australia. Antiviral Therapy, 20(2), 255.
    DOI
    2015 Boyd, M., Moore, C., Molina, J., Wood, R., Madero, J., Wolff, M., . . . Cooper, D. (2015). Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: An exploratory analysis. The Lancet HIV, 2(2), 42-51.
    DOI Scopus37 WoS33 Europe PMC30
    2015 Cummins, N., Neuhaus, J., Chu, H., Neaton, J., Wyen, C., Rockstroh, J., . . . Badley, A. (2015). Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis. EBioMedicine, 2(7), 706-712.
    DOI Scopus12 WoS10 Europe PMC7
    2015 Boyd, M., Donovan, B., Prestage, G., Chen, M., Petoumenos, K., Gray, R., . . . Klausner, J. (2015). Is it time to rethink syphilis control?. Clinical Infectious Diseases, 60(2), 325-326.
    DOI Scopus4 WoS4 Europe PMC3
    2015 Templeton, D., Wright, S., McManus, H., Lawrence, C., Russell, D., Law, M., . . . Boyd, M. (2015). Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD). BMC Infectious Diseases, 15(1), 1-8.
    DOI Scopus3 Europe PMC2
    2015 Wright, S., Law, M., Cooper, D., Keen, P., McDonald, A., Middleton, M., . . . Sasisopin, A. (2015). Temporal trends of time to antiretroviral treatment initiation, interruption and modification: Examination of patients diagnosed with advanced HIV in Australia. Journal of the International AIDS Society, 18(1), 19463.
    DOI Scopus4 Europe PMC3
    2015 McManus, H., Hoy, J., Woolley, I., Boyd, M., Kelly, M., Mulhall, B., . . . Law, M. (2015). Recent trends in early stage response to combination antiretroviral therapy in Australia. Antiviral Therapy, 20(2), 131-139.
    DOI Scopus3 WoS3 Europe PMC2
    2015 McManus, H., Petoumenos, K., Brown, K., Baker, D., Russell, D., Read, T., . . . Law, M. G. (2015). Loss to follow-up in the Australian HIV Observational Database. ANTIVIRAL THERAPY, 20(7), 731-741.
    DOI WoS11 Europe PMC6
    2015 McManus, H., Petoumenos, K., Brown, K., Baker, D., Russell, D., Read, T., . . . Law, M. G. (2015). Loss to follow-up in the Australian HIV Observational Database. ANTIVIRAL THERAPY, 20(7), 731-741.
    DOI WoS11 Europe PMC6
    2015 Bernardino, J. I., Mocroft, A., Mallon, P. W., Wallet, C., Gerstoft, J., Russell, C., . . . Arribas, J. R. (2015). Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. LANCET HIV, 2(11), E464-E473.
    DOI WoS41 Europe PMC27
    2015 Beyrer, C., Birx, D. L., Bekker, L. -G., Barre-Sinoussi, F., Cahn, P., Dybul, M. R., . . . Montaner, J. S. (2015). The Vancouver Consensus: antiretroviral medicines, medical evidence, and political will. LANCET, 386(9993), 505-507.
    DOI WoS15 Europe PMC12
    2014 Raffi, F., Babiker, A. G., Richert, L., Molina, J. -M., George, E. C., Antinori, A., . . . Pozniak, A. (2014). Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. LANCET, 384(9958), 1942-1951.
    DOI WoS92 Europe PMC71
    2014 Haskelberg, H., Pocock, N., Amin, J., Ebeling, P., Emery, S., & Carr, A. (2014). Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine. PLoS ONE, 9(4), e94858-1-e94858-8.
    DOI WoS4 Europe PMC3
    2014 Haskelberg, H., Cordery, D., Amin, J., Kelleher, A., Cooper, D., & Emery, S. (2014). HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine. PLoS ONE, 9(3), e93333-1-e93333-7.
    DOI WoS2 Europe PMC2
    2014 McManus, H., Petoumenos, K., Franic, T., Kelly, M., Watson, J., O’Connor, C., . . . Law, M. (2014). Determinants of suicide and accidental or violent death in the Australian HIV Observational Database. PLoS ONE, 9(2), e89089-1-e89089-8.
    DOI WoS11 Europe PMC10
    2014 Wright, S., Hoy, J., Mulhall, B., O'connor, C., Petoumenos, K., Read, T., . . . Boyd, M. (2014). Determinants of viremia copy-years in people with HIV/AIDS after initiation of antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 66(1), 55-64.
    DOI Scopus11 WoS10 Europe PMC8
    2014 Holt, S., Gracey, D., Levy, M., Mudge, D., Irish, A., Walker, R., . . . Boyd, M. (2014). A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection. AIDS Research and Therapy, 11(1), 35-1-35-10.
    DOI Scopus8 WoS8 Europe PMC6
    2014 Revell, A., Boyd, M., Wang, D., Emery, S., Gazzard, B., Reiss, P., . . . Larder, B. (2014). A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy. HIV Medicine, 15(7), 442-448.
    DOI Scopus3 WoS2 Europe PMC1
    2014 Haskelberg, H., Mallon, P., Hoy, J., Amin, J., Moore, C., Phanuphak, P., . . . Emery, S. (2014). Bone mineral density over 96 weeks in adults failing first-line therapy randomised to raltegravir/lopinavir/ritonavir compared to standard second-line therapy. Journal of Acquired Immune Deficiency Syndromes, 67(2), 161-168.
    DOI Scopus12 WoS13 Europe PMC12
    2014 Achhra, A., Boyd, M., Law, M., Matthews, G., Kelleher, A., & Cooper, D. (2014). Moving away from ritonavir, abacavir, tenofovir, and efavirenz (RATE) - Agents that concern prescribers and patients: A feasibility study and call for a trial. PLoS ONE, 9(6), e99530.
    DOI Scopus3 WoS3 Europe PMC2
    2014 Amin, J., Becker, S., Belloso, W., Boffito, M., Cooper, D., Crabtree-Ramirez, B., . . . Dolan, M. (2014). Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): A randomised, double-blind, placebo-controlled, non-inferiority trial. The Lancet, 383(9927), 1474-1482.
    DOI Scopus96 WoS97 Europe PMC70
    2013 Boyd, M. (2013). Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): A randomised, open-label, non-inferiority study. The Lancet, 381(9883), 2091-2099.
    DOI Scopus106 WoS99 Europe PMC76
    2013 Wright, S., Petoumenos, K., Boyd, M., Carr, A., Downing, S., O'Connor, C., . . . Law, M. (2013). Ageing and long-term CD4 cell count trends in HIV-positive patients with 5 years or more combination antiretroviral therapy experience. HIV Medicine, 14(4), 208-216.
    DOI Scopus15 WoS12 Europe PMC11
    2013 Wright, S., Boyd, M., Yunihastuti, E., Law, M., Sirisanthana, T., Hoy, J., . . . Petoumenos, K. (2013). Rates and factors associated with major modifications to first-line combination antiretroviral therapy: results from the Asia-Pacific region. PLoS ONE, 8(6), e64902-1-e64902-12.
    DOI Scopus12 WoS9 Europe PMC12
    2013 Achhra, A., & Boyd, M. (2013). Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: A review of the recent literature. AIDS Research and Therapy, 10(1), 33.
    DOI Scopus22 WoS19 Europe PMC16
    2013 Martin, A., Moore, C., Mallon, P., Hoy, J., Emery, S., Belloso, W., . . . Second-line study team. (2013). HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy. PLoS One, 8(10), e77138-1-e77138-9.
    DOI Scopus11 WoS10 Europe PMC8
    2013 Boyd, M., & Cooper, D. (2013). SPRING-2 the future of antiretroviral therapy. The Lancet Infectious Diseases, 13(11), 908-909.
    DOI Scopus4 WoS4 Europe PMC3
    2013 Martin, A., Moore, C., Mallon, P., Hoy, J., Emery, S., Belloso, W., . . . Boyd, M. (2013). Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy. AIDS, 27(15), 2403-2411.
    DOI Scopus26 WoS27 Europe PMC20
    2013 Boyd, M., & Donovan, B. (2013). Antiretroviral therapy: Dolutegravir sets SAIL(ING). The Lancet, 382(9893), 664-666.
    DOI Scopus3 WoS2
    2013 Schneider, K., Nwizu, C., Kaplan, R., Anderson, J., Wilson, D., Emery, S., . . . Boyd, M. (2013). The potential cost and benefits of raltegravir in simplified second-line therapy among HIV Infected Patients in Nigeria and South Africa. PLoS ONE, 8(2), e54435.
    DOI Scopus1 WoS1 Europe PMC1
    2013 Byakwaga, H., Petoumenos, K., Ananworanich, J., Zhang, F., Boyd, M., Sirisanthana, T., . . . Emery, S. (2013). Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: Results from the TREAT Asia HIV Observational Database. Journal of the International Association of Providers of AIDS Care, 12(4), 270-277.
    DOI Scopus3 Europe PMC2
    2013 Jansson, J., Wilson, D., Carr, A., Petoumenos, K., & Boyd, M. (2013). Currently available medications in resource-rich settings may not be sufficient for lifelong treatment of HIV. AIDS, 27(8), 1245-1251.
    DOI Scopus10 WoS10 Europe PMC10
    2013 Petoumenos, K., van Leuwen, M., Vajdic, C., Woolley, I., Chuah, J., Templeton, D., . . . Law, M. (2013). Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD). HIV Medicine, 14(2), 77-84.
    DOI WoS22 Europe PMC17
    2013 Guy, R., Wand, H., McManus, H., Vonthanak, S., Woolley, I., Honda, M., . . . Carr, A. (2013). Antiretroviral Treatment Interruption and Loss to Follow-Up in Two HIV Cohorts in Australia and Asia: Implications for 'Test and Treat' Prevention Strategy. AIDS PATIENT CARE AND STDS, 27(12), 681-691.
    DOI WoS12 Europe PMC12
    2012 Boyd, M., & Cooper, D. (2012). Optimisation of HIV care and service delivery: Doing more with less. The Lancet, 380(9856), 1860-1866.
    DOI Scopus12 WoS11 Europe PMC8
    2012 Carey, D., Pett, S., Bloch, M., Wand, H., MacRae, K., Beileiter, K., . . . Cooper, D. (2012). A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults. Journal of Acquired Immune Deficiency Syndromes, 60(2), 143-149.
    DOI Scopus17 WoS15 Europe PMC11
    2012 McManus, H., O'Connor, C., Boyd, M., Broom, J., Russell, D., Watson, K., . . . Law, M. (2012). Long-Term Survival in HIV Positive Patients with up to 15 Years of Antiretroviral Therapy. PLoS ONE, 7(11), e48839.
    DOI Scopus53 WoS54 Europe PMC44
    2012 Avihingsanon, A., Van Der Lugt, J., Singphore, U., Gorowara, M., Boyd, M., Ananworanich, J., . . . Ruxrungtham, K. (2012). Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: A pilot study. AIDS Research and Human Retroviruses, 28(10), 1170-1176.
    DOI Scopus3 WoS2
    2012 Boyd, M., & Mohapi, L. (2012). Stretching delivery of HIV health services. The Lancet, 380(9845), 865-867.
    DOI
    2012 Haskelberg, H., Hoy, J., Amin, J., Ebeling, P., Emery, S., Carr, A., . . . Woolley, I. (2012). Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS ONE, 7(6), 1-9.
    DOI Scopus55 WoS59 Europe PMC47
    2012 Boyd, M. (2012). Dolutegravir-a promising antiretroviral in development. The Lancet Infectious Diseases, 12(2), 90-91.
    DOI Scopus7 WoS7 Europe PMC4
    2011 Revell, A., Wang, D., Boyd, M., Emery, S., Pozniak, A., De Wolf, F., . . . Larder, B. (2011). The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool. AIDS, 25(15), 1855-1863.
    DOI Scopus21 WoS19 Europe PMC16
    2011 Byakwaga, H., Kelly, M., Purcell, D., French, M., Amin, J., Lewin, S., . . . Emery, S. (2011). Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4 <sup>+</sup> T-cell response: A randomized controlled trial. Journal of Infectious Diseases, 204(10), 1532-1540.
    DOI Scopus45 WoS42 Europe PMC36
    2011 Martin, A., Amin, J., Emery, S., Baker, D., Carr, A., Cooper, D., & Bloch, M. (2011). Predictors of Limb Fat Gain in HIV Positive Patients Following a Change to Tenofovir-Emtricitabine or Abacavir-Lamivudine. PLoS ONE, 6(10), e26885.
    DOI Europe PMC4
    2011 Kowalska, J. D., Friis-Moller, N., Kirk, O., Bannister, W., Mocroft, A., Sabin, C., . . . Lundgren, J. D. (2011). The Coding Causes of Death in HIV (CoDe) Project Initial Results and Evaluation of Methodology. EPIDEMIOLOGY, 22(4), 516-523.
    DOI WoS80 Europe PMC65
    2011 Law, M., Woolley, I., Templeton, D., Roth, N., Chuah, J., Mulhall, B., . . . Australian HIV Observational Database (AHOD).. (2011). Trends in detectable viral load by calendar year in the Australian HIV observational database. Journal of the International AIDS Society, 14(1), 10-1-10-7.
    DOI WoS26 Europe PMC21
    2011 Law, M., Woolley, I., Templeton, D., Roth, N., Chuah, J., Mulhall, B., . . . Australian HIV Observational Database (AHOD).. (2011). Trends in detectable viral load by calendar year in the Australian HIV observational database. Journal of the International AIDS Society, 14(1), 10-1-10-7.
    DOI WoS26 Europe PMC21
    2011 Wright, S. T., Carr, A., Woolley, I., Giles, M., Hoy, J., Cooper, D. A., & Law, M. G. (2011). CD4 Cell Responses to Combination Antiretroviral Therapy in Patients Starting Therapy at High CD4 Cell Counts. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 58(1), 72-79.
    DOI WoS9 Europe PMC7
    2011 Wilson, D., Grulich, A., & Boyd, M. (2011). Overly optimistic forecasts for the impact of treatment of hiv prevention for men who have sex with men. Clinical Infectious Diseases, 53(6), 611-612.
    DOI Scopus2 WoS1 Europe PMC1
    2010 Zhou, J., Li, P., Kumarasamy, N., Boyd, M., Chen, Y., Sirisanthana, T., . . . Pujari, S. (2010). Deferred modification of antiretroviral regimen following documented treatment failure in Asia: Results from the TREAT Asia HIV Observational Database (TAHOD). HIV Medicine, 11(1), 31-39.
    DOI Scopus19 WoS17 Europe PMC14
    2010 Martin, A., Amin, J., Cooper, D. A., Carr, A., Kelleher, A. D., Bloch, M., . . . Emery, S. (2010). Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. AIDS, 24(17), 2657-2663.
    DOI WoS41 Europe PMC32
    2010 Carey, D., Amin, J., Boyd, M., Petoumenos, K., & Emery, S. (2010). Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: Systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy, 65(9), 1878-1888.
    DOI Scopus32 WoS28 Europe PMC21
    2010 Boyd, M., & Hill, A. (2010). Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era. PharmacoEconomics, 28(SUPPL. 1), 17-34.
    DOI Scopus12 WoS10 Europe PMC5
    2010 Boyd, M. (2010). Current and future management of treatment failure in low- and middle-income countries. Current Opinion in HIV and AIDS, 5(1), 83-89.
    DOI Scopus14 WoS12 Europe PMC11
    2010 Boyd, M., & Nwizu, C. (2010). Operational research in HIV priority areas: the African way. The Lancet, 376(9734), 4-6.
    DOI Scopus1 WoS2 Europe PMC2
    2009 Boyd, M., Emery, S., & Cooper, D. (2009). Antiretroviral roll-out: the problem of second-line therapy. The Lancet, 374(9685), 185-186.
    DOI Scopus16 WoS15 Europe PMC13
    2009 Boyd, M. (2009). Improvements in antiretroviral therapy outcomes over calendar time. Current Opinion in HIV and AIDS, 4(3), 194-199.
    DOI Scopus39 WoS35 Europe PMC34
    2009 Byakwaga, H., Murray, J., Petoumenos, K., Kelleher, A., Law, M., Boyd, M., . . . Cooper, D. (2009). Evolution of CD4<sup>+</sup> T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression. AIDS Research and Human Retroviruses, 25(6), 569-576.
    DOI Scopus4 Europe PMC6
    2009 Byakwaga, H., Zhou, J., Petoumenos, K., Law, M., Boyd, M., Emery, S., . . . Mallon, P. (2009). Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy. HIV Medicine, 10(3), 143-151.
    DOI Scopus3 WoS3 Europe PMC2
    2009 Boyd, M. (2009). Clinical research in low- and middle-income countries.. The virtual mentor : VM, 11(7), 511-515.
    DOI
    2008 Colebunders, R., French, M., Oelrichs, R., & Boyd, M. (2008). Editorial introductions. Current Opinion in HIV and AIDS, 3(4), vii-viii.
    DOI
    2008 Boyd, M., & Pett, S. (2008). HIV fusion inhibitors: A review. Australian Prescriber, 31(3), 66-69.
    Scopus1
    2008 Boyd, M., & Byakwaga, H. (2008). Considering the benefits of disease-specific interventions on overall public health. The Lancet Infectious Diseases, 8(5), 278.
    DOI Scopus1 WoS1 Europe PMC1
    2008 Oelrichs, R., & Boyd, M. (2008). Evidence and policy in the globalized response to AIDS. Current Opinion in HIV and AIDS, 3(4), 477-480.
    DOI
    2008 Boyd, M., Truman, M., Hales, G., Anderson, J., Dwyer, D., & Carr, A. (2008). A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study). Antiviral Therapy, 13(3), 449-453.
    Scopus8 WoS7 Europe PMC5
    2007 Boyd, M., & Cooper, D. (2007). Second-line combination antiretroviral therapy in resource-limited settings: Facing the challenges through clinical research. AIDS, 21(SUPPL. 4), S55-S63.
    DOI Scopus31 WoS26 Europe PMC26
    2007 Srasuebkul, P., Ungsedhapand, C., Ruxrungtham, K., Boyd, M., Phanuphak, P., Cooper, D., & Law, M. (2007). Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment. HIV Medicine, 8(1), 46-54.
    DOI Scopus13 WoS10 Europe PMC10
    2007 Boyd, M., Menon, P., Graves, S., & Gordon, D. (2007). A febrile illness with generalized papular rash involving the palms and soles. Clinical Infectious Diseases, 44(5), 704-756.
    DOI
    2007 Snelling, T., Ossowicz, C., & Boyd, M. (2007). Case report: Co-infections in an HIV-infected man from Malawi. American Journal of Tropical Medicine and Hygiene, 76(1), 180-181.
    DOI
    2007 Autar, R., Boyd, M., Wit, F., Ruxrungtham, K., Sankote, J., Lange, J., . . . Reiss, P. (2007). Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen. Antiviral Therapy, 12(8), 1265-1271.
    Scopus5 WoS6 Europe PMC5
    2007 Cooper, D., Cahn, P., Lewin, S., Kaldor, J., McClure, C., Kort, R., & Boyd, M. (2007). The Sydney Declaration: a call to scale up research. Lancet, 370(9581), 7-8.
    DOI Scopus13 Europe PMC10
    2007 Boyd, M. (2007). Indinavir: The forgotten HIV-protease inhibitor. Does it still have a role?. Expert Opinion on Pharmacotherapy, 8(7), 957-964.
    DOI Scopus13 WoS13 Europe PMC9
    2007 Kerr, S., Duncombe, C., Avihingsanon, A., Ananworanich, J., Boyd, M., Sopa, B., . . . Ruxrungtham, K. (2007). Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens. Journal of the International Association of Physicians in AIDS Care, 6(1), 36-46.
    DOI Scopus9 Europe PMC6
    2007 Boyd, M., & Hedger, S. (2007). An unusual cause of severe metabolic acidosis [5]. Medical Journal of Australia, 186(3), 158.
    2006 Boyd, M., & Reiss, P. (2006). The long-term consequences of antiretroviral therapy: A review. Journal of HIV Therapy, 11(2), 26-35.
    Scopus15 Europe PMC12
    2006 Boyd, M., Clezy, K., Lindley, R., & Pearce, R. (2006). Pandemic influenza: Clinical issues. Medical Journal of Australia, 185(10 SUPPL.), S44-S47.
    Scopus21 Europe PMC13
    2006 Boyd, M., & Reiss, P. (2006). Erratum: The long-term effects of antiretroviral therapy: A review (Journal of HIV Therapy 11, 2 (28)). Journal of HIV Therapy, 11(3).
    2006 Boyd, M., Carr, A., Ruxrungtham, K., Srasuebkul, P., Bien, D., Law, M., . . . Reiss, P. (2006). Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz. Journal of Infectious Diseases, 194(5), 642-650.
    DOI Scopus24 WoS26 Europe PMC19
    2006 Boyd, M., Srasuebkul, P., Ruxrungtham, K., Mackenzie, P., Uchaipichat, V., Stek, M., . . . Miners, J. (2006). Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenetics and Genomics, 16(5), 321-329.
    DOI Scopus46 WoS35 Europe PMC24
    2006 Boyd, M., Siangphoe, U., Ruxrungtham, K., Reiss, P., Mahanontharit, A., Lange, J., . . . Burger, D. (2006). The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity. Journal of Antimicrobial Chemotherapy, 57(6), 1161-1167.
    DOI Scopus19 WoS17 Europe PMC8
    2006 Boyd, M., Dixit, N., Siangphoe, U., Buss, N., Salgo, M., Lange, J., . . . Ruxrungtham, K. (2006). Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: A randomized, controlled trial (HIV-NAT 012). Journal of Infectious Diseases, 194(9), 1319-1322.
    DOI Scopus11 WoS9 Europe PMC6
    2006 Boyd, M., Burger, D., Phanuphak, P., & Cooper, D. (2006). Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis [4]. AIDS, 20(7), 1083-1085.
    DOI Scopus3 WoS2 Europe PMC2
    2006 Boyd, M., Srasuebkul, P., Khongphattanayothin, M., Ruxrungtham, K., Hassink, E., Duncombe, C., . . . Phanuphak, P. (2006). Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: A randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). Antiviral Therapy, 11(2), 223-232.
    Scopus15 WoS12 Europe PMC10
    2006 Kong, A., Koukourou, A., Boyd, M., & Crowe, G. (2006). Metastatic adenocarcinoma mimicking 'target sign' of cerebral tuberculosis. Journal of Clinical Neuroscience, 13(9), 955-958.
    DOI Scopus13 WoS8 Europe PMC7
    2006 Boyd, M., & Rogers, W. (2006). Industry and bioethics: What price the relationship? [3]. PLoS Medicine, 3(6), 0933.
    DOI Scopus1 WoS1 Europe PMC1
    2005 Boyd, M., Siangphoe, U., Ruxrungtham, K., Duncombe, C., Stek, M., Lange, J., . . . Phanuphak, P. (2005). Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009. HIV Medicine, 6(6), 410-420.
    DOI Scopus15 WoS11 Europe PMC6
    2005 Boyd, M., Mootsikapun, P., Burger, D., Chuenyam, T., Ubolyam, S., Mahanontharit, A., . . . Ruxrungtham, K. (2005). Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Antiviral Therapy, 10(2), 301-307.
    Scopus40 WoS37 Europe PMC27
    2004 Ananworanich, J., Cheunyam, T., Teeratakulpisarn, S., Boyd, M., Ruxrungtham, K., Lange, P., . . . Phanuphak, P. (2004). Creation of a drug fund for post-clinical trial access to antiretrovirals. Lancet, 364(9428), 101-102.
    DOI Scopus16 WoS15 Europe PMC10
    2004 Law, W., Duncombe, C., Mahanontharit, A., Boyd, M., Ruxrungtham, K., Lange, J., . . . Dore, G. (2004). Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS, 18(8), 1169-1177.
    DOI Scopus125 WoS113 Europe PMC89
    2004 Ruxrungtham, K., Boyd, M., Bellibas, S., Zhang, X., Dorr, A., Kolis, S., . . . Patel, I. (2004). Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. Journal of Clinical Pharmacology, 44(7), 793-802.
    DOI Scopus25 WoS20 Europe PMC16
    2003 Law, W., Dore, G., Duncombe, C., Mahanontharit, A., Boyd, M., Ruxrungtham, K., . . . Cooper, D. (2003). Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS, 17(15), 2191-2199.
    DOI WoS85 Europe PMC64
    2003 Law, W., Dore, G., Duncombe, C., Mahanontharit, A., Boyd, M., Ruxrungtham, K., . . . Cooper, D. (2003). Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS, 17(15), 2191-2199.
    DOI Scopus98
    2003 Boyd, M., Zhang, X., Dorr, A., Ruxrungtham, K., Kolis, S., Nieforth, K., . . . Patel, I. (2003). Lack of Enzyme-Inducing Effect of Rifampicin on the Pharmacokinetics of Enfuvirtide. Journal of Clinical Pharmacology, 43(12), 1382-1391.
    DOI Scopus41 WoS36 Europe PMC26
    2003 Boyd, M., Aarnoutse, R., Ruxrungtham, K., Stek, M., Van Heeswijk, R., Lange, J., . . . Burger, D. (2003). Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. Journal of Acquired Immune Deficiency Syndromes, 34(2), 134-139.
    DOI Scopus19 WoS19 Europe PMC14
    2003 Burger, D., Boyd, M., Duncombe, C., Felderhof, M., Mahanontharit, A., Ruxrungtham, K., . . . Reiss, P. (2003). Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. Journal of Antimicrobial Chemotherapy, 51(5), 1231-1238.
    DOI Scopus57 WoS50 Europe PMC34
  • Book Chapters

    Year Citation
    2018 Boyd, M., & Crowe, S. (2018). Indinavir. In M. L. Grayson, S. E. Cosgrove, S. Crowe, W. Hope, J. S. McCarthy, J. Mills, . . . D. L. Paterson (Eds.), Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition (pp. 4061-4074). Boca Raton, FL; USA: CRC Press.
    DOI
    2010 Boyd, M. A., & Cooper, D. A. (2010). Antiretroviral Therapy. In R. G. Finch, D. Greenwood, S. R. Norrby, & R. J. Whitley (Eds.), Antibiotic and Chemotherapy (9 ed., pp. 427-451). Elsevier Health Sciences.
  • Conference Items

    Year Citation
    2016 Boyd, M. A. (2016). HIV in Myanmar.. Poster session presented at the meeting of 2016 International Congress for Tropical Medicine and Malaria. Brisbane, Queensland, Australia.
    2014 Holt, S., Gracey, D., Mudge, D., Irish, A., Sevastos, J., Walker, R., . . . Boyd, M. (2014). RENAL FUNCTION TESTING IN PATIENTS ON TENOFOVIR ANTIVIRAL THERAPY. Poster session presented at the meeting of NEPHROLOGY. WILEY-BLACKWELL.
Grants and Funding
Category 1
2014 - 2017 Clinical Development Award clinical support for 4 years NHMRC 2014: $404,884 AUD
2013 Project Grant award support of the SECOND-LINE study NHMRC $449,584.40 AUD

 

Category 2
2014 Australian Award Fellowship support of the combined UNSW/U Sydney Global Intensive Professional Program in HIV (GIPPH) Australian Commonwealth Government Department of Foreign Affairs & Trade. $656,888.
2013 Australian Award Fellowships support of the combined UNSW/U Sydney Global Intensive Professional Program in HIV (GIPPH) AusAID $698,160.00

 

Category 3
2015 In support of the development of capacity to measure ARV levels in human tissues: Merck & Co. IISP grant $20,000 UAD
2015 Award in support of Faster and smarter identification of at-risk sexually transmitted infection patients via online, mobile and social platforms auDA foundation $20,000 AUD
2014 Award in project support of The association between virological failure and lopinavir plasma drug levels in the SECOND-LINE trial Gilead Australia Fellowship Research Grants 2015: $30,000 AUD
2014 Independent initiative grant support for an analysis of bone turnover, immune activation and inflammatory biomarkers in the SECOND-LINE DXA-substudy, Grants Merck Global Affairs 2014: $304,064 AUD
2012 Award for support of the RATE study Gilead Australia Fellowship Research Grants 2013: $20,000 AUD
2012 Support of the SECOND-LINE study The Foundation for AIDS Research 2012: $125,000 USD
2012 Support of the SECOND-LINE study Merck & Co. $1,000,000 USD.
2011 Support of the SECOND-LINE study The Foundation for AIDS Research 2011: $125,000 USD
2010 Support of the SECOND-LINE study The Foundation for AIDS Research 2010: $125,000 USD
2009 Support of the SECOND-LINE study Abbott Inc. $600,000 AUD
2009 Support of the SECOND-LINE study Merck & Co. 2009: $1,100,000 USD
2008 Support of the Encore program Bill and Melinda Gates Foundation $12,416,901 USD
    Expand
  • Board Memberships

    Date Role Board name Institution name Country
    2015 - ongoing Member , Scientific and Program Committee of the Asia Pacific AIDS & Co-infections Asia Pacific AIDS & Co-infections (APAAC) Conference 2016 Asia Pacific AIDS & Co-infections Asia Pacific AIDS & Co-infections (APAAC)
  • Committee Memberships

    Date Role Committee Institution Country
    2015 - ongoing Chair ASHM International Advisory Group
    2014 - ongoing Member Australian National HIV Pre-Exposure Prophylaxis (PrEP) Guidance Committee
    2014 - ongoing Chair RACP Working Group
    2014 - ongoing President Australasian Society for HIV Medicine (ASHM)
    2014 - ongoing Chair Gilead ‘HIV and the Body’ educational meeting faculty
    2013 - ongoing Chair Lyell McEwin Hospital, Discipline of Medicine, School of Medicine University of Adelaide
    2013 - ongoing Member NEAT-id (European Treatment Network for HIV, Hepatitis and Global Infectious Diseases)
    2013 - ongoing Member Australasian Society for HIV Medicine (ASHM) Clinical Guidance Committee
    2013 - ongoing Chair National Program Theme B Committee for the ASHM 2013 National Conference
    2012 - ongoing Member Kirby Institute Higher Degree Committee and Annual Post-Graduate Progress Review academic staff
    2012 - ongoing Member ASID Prosthetic Joint Infection Trial Steering Committee
    2012 - ongoing Member ASHM NSW HIV Shared Care Workshop Committee
    2012 - ongoing Member Australian Society for Infectious Disease (ASID) Native Joint Infection Trial Steering Committee
    2011 - 2014 Vice-President Australasian Society for HIV Medicine (ASHM)
    2010 - ongoing Member Australian HIV Observational Database (AHOD) Steering Committee
    2009 - ongoing Vice-President Australasian Society for HIV Medicine
    2009 - ongoing Member ASHM Risk Management and Audit Sub-Committee
    2005 - 2009 Board Member Australasian Society for HIV Medicine
    2005 - ongoing Board Member Australasian Society for HIV Medicine (ASHM)
    1999 - 2005 Member Australasian Society for HIV Medicine
  • Consulting/Advisories

    Date Institution Department Organisation Type Country
    2014 - ongoing International Advisory Board, Lancet HIV
    2014 - ongoing Merck Australian HIV Advisory Board
    2013 - ongoing ASHM NSW Expert Advisory Committee
    2013 - ongoing Gilead Sciences International HIV Advisory Board
  • Editorial Boards

    Date Role Editorial Board Name Institution Country
    2015 - ongoing Editor-In-chief AIDS Research & Therapy BMC open access journal
  • Industry Partnerships

    Date Engagement Type Partner Name
    2014 - 2016 Consultant Honorary Consultant in HIV Medicine, The Albion Centre
    2013 - ongoing Consultant HIV and Infectious Diseases Specialist Consultant, Holdsworth House Medical Practice
  • Position: Chair of Medicine
  • Phone: 0881829653
  • Email: mark.boyd@adelaide.edu.au
  • Building: Lyell McEwin Hospital
  • Org Unit: Medicine

Connect With Me
External Profiles